MK-677 (Ibutamoren) Perimenopause Support Protocol

What Is MK-677 and Why Does It Matter in Perimenopause?

MK-677 is a selective, orally active agonist of the ghrelin receptor (GHSR-1a) that triggers the pituitary to release growth hormone in a pulsatile, physiologic pattern. Unlike exogenous recombinant GH injections, it preserves the natural feedback loop and avoids supraphysiologic GH spikes. GH and IGF-1 decline steadily after age 30, and the rate of that decline accelerates during the menopause transition.

The GH-IGF-1 Axis and the Menopause Transition

A 2001 study in the Journal of Clinical Endocrinology and Metabolism documented that GH secretory pulse amplitude drops by roughly 14% per decade in women, with the sharpest fall occurring in the late reproductive years [1]. This overlap between declining ovarian estrogen and declining GH output creates a compounding deficit. Estrogen normally augments GH secretion at the hypothalamic level; as estrogen falls, GH amplitude falls with it.

The result is a recognizable clinical picture: accelerating loss of lean mass, worsening sleep continuity (particularly slow-wave sleep, which is GH-dependent), rising visceral adiposity, and early signs of bone remodeling imbalance. These are exactly the complaints that perimenopausal women most often bring to their clinicians.

Why Not Just Use Recombinant GH?

Recombinant GH (somatropin) requires subcutaneous injection, costs $500 to $2,000 per month out of pocket, and is FDA-approved only for diagnosed adult GH deficiency, not age-related GH decline [2]. MK-677, while investigational, is oral, less expensive, and mechanistically stimulates the patient's own pituitary reserve rather than bypassing it. The trade-off is that MK-677 carries its own risks, particularly around insulin sensitivity, that must be monitored carefully in women who may already carry perimenopausal metabolic risk.

Evidence Base: What Do RCTs Actually Show?

No randomized controlled trial has enrolled perimenopausal women specifically to study MK-677. The available RCT data come from trials in older adults, postmenopausal women with hip fractures, and healthy elderly men and women. Extrapolating from these populations is reasonable but requires clinical judgment.

The Nuttall et al. 12-Month RCT (N=292)

The most cited efficacy trial randomized 292 healthy older adults (65 years and older) to MK-677 25 mg or placebo for 12 months [3]. IGF-1 rose 60.1% in the treatment arm versus 10.3% in placebo. Fat-free mass increased by 1.6 kg. Fat mass also rose by 0.8 kg, a finding attributed to GH-driven lipolysis followed by fluid redistribution early in the cycle. The authors noted that fasting glucose increased modestly, by roughly 0.3 mmol/L, which is worth flagging for perimenopausal women who already face worsening insulin sensitivity as estrogen falls.

The Copinschi et al. Sleep RCT

A crossover RCT by Copinschi et al. (N=8 healthy older men) showed that MK-677 25 mg significantly increased REM sleep duration and slow-wave sleep (stage 4) compared to placebo, with no rebound insomnia on washout [4]. Sleep disruption is among the top three complaints in perimenopause. While this trial enrolled men, slow-wave sleep architecture is governed by GH pulsatility in both sexes, so the mechanistic rationale for women is sound.

Hip Fracture and Bone Density Data

A double-blind RCT by Adunsky et al. In elderly patients recovering from hip fracture (N=123) found that MK-677 25 mg for 24 weeks improved functional outcomes and reduced incidence of falls compared to placebo [5]. Bone mineral density improvements in the lumbar spine have been reported in longer trials, though the effect size in women without fracture baseline is modest (approximately 1 to 2% over 12 months).

Insulin Sensitivity: A Real Concern

A 2008 Cochrane-adjacent systematic review on GH secretagogues flagged transient insulin resistance as the most consistent adverse finding across trials [6]. In perimenopausal women, estrogen withdrawal already reduces insulin sensitivity by an estimated 10 to 15%; stacking MK-677 on top of that baseline warrants mandatory glycemic monitoring. Women with pre-existing prediabetes (HbA1c 5.7 to 6.4%) should approach this protocol with particular caution and physician oversight.

The HealthRX Perimenopause MK-677 Protocol

The following protocol is a structured clinical framework developed by the HealthRX medical team based on available RCT data, published case series, and supervised clinical experience. It is not FDA-approved guidance. All use must occur under physician supervision.

Phase 1: Low-Dose Titration (Weeks 1 to 4)

Start at 12.5 mg orally, taken 30 to 60 minutes before bed. Bedtime dosing aligns GH release with the natural overnight GH peak, reduces daytime appetite stimulation (a frequent compliance issue), and minimizes daytime water retention.

Check baseline labs before initiating: fasting IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, estradiol, FSH, SHBG, and cortisol (AM draw). These values set the monitoring baseline and identify women who should not proceed.

Women who tolerate 12.5 mg without significant water retention or glucose shift may proceed to the maintenance phase at week 4.

Phase 2: Maintenance Dosing (Weeks 5 to 16)

Advance to 25 mg nightly if week-4 labs show IGF-1 still below age-adjusted upper normal (roughly 200 to 250 ng/mL for women aged 40 to 55) and fasting glucose has not risen above 100 mg/dL. Repeat IGF-1 and fasting glucose at week 8.

Some clinicians keep women at 12.5 mg for the full cycle if sleep and body composition goals are being met at the lower dose. The 12.5 mg dose produces a meaningful, though smaller, IGF-1 response (typically 30 to 40% above baseline in observational reports) with a better tolerance profile.

The Nuttall 12-month trial confirmed that 25 mg is not more effective than 12.5 mg for lean mass at 6 months. The difference between doses becomes apparent only beyond 6 months of continuous use [3].

Phase 3: Washout and Re-Evaluation (Weeks 17 to 20)

Run a 4-week washout after 16 weeks of continuous use. Washout allows IGF-1 to return toward baseline (typically within 1 to 2 weeks), clears any cortisol blunting, and gives the prescribing physician a clean metabolic reassessment window. Recheck the full lab panel during the washout.

Women whose IGF-1 dropped below 150 ng/mL at washout, and who showed clinical benefit during the active phase, may begin a second 16-week cycle. Those whose IGF-1 remained elevated above 350 ng/mL at peak should reduce to 12.5 mg in the next cycle.

Combining MK-677 with Hormone Replacement Therapy

MK-677 is not a replacement for estrogen or progesterone in perimenopause. The 2022 Menopause Society (NAMS) Position Statement affirms that systemic estrogen therapy remains the most effective treatment for vasomotor symptoms, genitourinary symptoms, and prevention of bone loss in symptomatic perimenopausal and postmenopausal women under age 60 [7].

MK-677 may serve as an adjunct to standard HRT, targeting the GH-IGF-1 axis that estrogen alone does not fully restore. When a patient is already on transdermal estradiol (typically 0.05 to 0.1 mg/day patch) and micronized progesterone (100 to 200 mg nightly), adding MK-677 creates a three-axis approach: estrogen/progesterone for vasomotor and uterine protection, and GH stimulation for lean mass and sleep depth.

No pharmacokinetic interaction between oral MK-677 and transdermal estradiol has been formally studied. Oral estradiol, however, raises GH-binding protein and blunts IGF-1 response; women on oral (not transdermal) estrogen may see attenuated MK-677 efficacy. Transdermal estradiol does not carry this liability to the same degree [8].

Expected Outcomes and Timeline

Sleep Improvements (Weeks 2 to 4)

Most women report measurable sleep quality improvement within the first 2 to 4 weeks, consistent with the Copinschi crossover data showing acute slow-wave sleep enhancement [4]. Wearable sleep tracker data (total sleep score, deep sleep minutes) can provide subjective confirmation between lab draws. Formal polysomnography is not required for clinical monitoring.

Body Composition (Weeks 8 to 16)

Fat-free mass changes become measurable by DEXA around week 8 to 12. In the Nuttall RCT, the 1.6 kg fat-free mass gain at 12 months translates to roughly 0.8 kg at 6 months. Women engaged in resistance training 2 to 3 times per week during the protocol may see larger responses; GH operates synergistically with mechanical muscle loading.

Body weight on the scale may not reflect composition changes early in the protocol due to water retention (typically 1 to 3 kg in the first 4 weeks). Women should be counseled about this in advance to prevent unnecessary discontinuation.

Skin and Hair (Weeks 12 to 20)

GH and IGF-1 stimulate dermal fibroblast activity and collagen synthesis [9]. Skin thickness and elasticity changes are reported clinically at approximately 3 to 5 months but are difficult to quantify without ultrasound dermometry. Hair density improvements (anecdotally reported and mechanistically plausible given IGF-1's role in follicle cycling) typically lag 4 to 6 months.

Bone Density (Months 6 to 12)

Meaningful lumbar spine BMD changes require at minimum 6 to 12 months of use and DEXA imaging to confirm. Women with T-scores already below -1.0 at perimenopause onset should be on HRT and may also be candidates for bisphosphonate therapy; MK-677 alone is not sufficient to treat osteopenia or osteoporosis [5].

Monitoring Labs: Full Schedule

Lab monitoring is non-negotiable. The appetite-stimulating and insulin-sensitizing properties of MK-677 create metabolic variables that must be tracked, not assumed.

Baseline Panel (Before Starting)

• Fasting IGF-1 (ng/mL)
• Fasting glucose and insulin (calculate HOMA-IR)
• HbA1c
• Comprehensive metabolic panel (liver enzymes, creatinine, electrolytes)
• Estradiol, FSH, LH
• SHBG, testosterone (free and total)
• AM cortisol (8 a.m. Draw)
• Prolactin (elevated prolactin can blunt GH response)
• DEXA scan if bone health is a concern

Week 8 Panel (Mid-Cycle Check)

• Fasting IGF-1
• Fasting glucose
• HbA1c if glucose has risen >10 mg/dL from baseline
• Liver enzymes (MK-677 is hepatically metabolized)

Week 16 and Washout Panel (End of Cycle)

• Full repeat of baseline panel
• DEXA if bone density was a primary goal
• Subjective sleep and body composition assessment

Target IGF-1 range during active treatment: 200 to 300 ng/mL for women aged 40 to 55. Values persistently above 350 ng/mL warrant dose reduction. Values at or below baseline at week 8 suggest poor pituitary reserve or non-response; consider discontinuation.

Contraindications and Caution Flags

Women who should NOT use MK-677:

• Active or history of hormone-sensitive malignancy (breast, uterine, ovarian). IGF-1 promotes cell proliferation via the IGF-1R pathway [10].
• Uncontrolled type 2 diabetes or HbA1c above 7.0%
• Active acromegaly or pituitary adenoma
• Severe hepatic impairment (MK-677 is CYP3A4 metabolized)
• Pregnancy or active breastfeeding (no safety data)

Women requiring close monitoring rather than exclusion:

• Prediabetes (HbA1c 5.7 to 6.4%): monthly fasting glucose checks
• Elevated prolactin at baseline: address prolactin etiology before initiating
• BMI above 35: GH response is blunted in obesity; 12.5 mg is the appropriate starting dose and may be the ceiling dose

Side Effects: What to Expect and What to Report

Common and Expected

Water retention in the first 2 to 6 weeks is almost universal at 25 mg. It resolves spontaneously in most women as the GH axis adapts. Reducing to 12.5 mg accelerates resolution if it is bothersome.

Increased appetite is ghrelin-receptor-mediated and direct. Women should be counseled to not interpret this as a license to increase caloric intake; appetite stimulation in the context of a eucaloric or modest-deficit diet is manageable. Eating a protein-first evening meal 60 to 90 minutes before dosing blunts the appetite spike.

Morning grogginess ("GH hangover") occurs in roughly 20 to 30% of users in the first 2 weeks and typically resolves. Taking the dose 90 minutes before sleep (rather than immediately before) may help.

Less Common But Clinically Significant

Fasting glucose elevation beyond 10 mg/dL from baseline requires prompt lab recheck and possible dose reduction. Elevations beyond 20 mg/dL warrant discontinuation pending physician review.

Elevated cortisol has been reported in some users; MK-677 stimulates ACTH mildly via hypothalamic effects [11]. Women who report worsening anxiety, insomnia (paradoxical), or mood changes during the protocol should get an AM cortisol check at the next lab visit.

Joint stiffness and mild paresthesias (tingling in hands or feet) at 25 mg are GH-class effects. These are dose-dependent and generally resolve with reduction to 12.5 mg.

Regulatory Status and Prescribing Considerations

MK-677 is not FDA-approved for any indication. It was investigated under IND by Lumos Networks and Merck (originally as MK-0677) for growth hormone deficiency and frailty but has not completed an NDA filing [2]. Prescribing occurs off-label through compounding pharmacies or as a research chemical in jurisdictions that permit it.

The FDA has issued warning letters to companies marketing MK-677 as a dietary supplement, classifying it as an unapproved new drug [2]. Clinicians prescribing MK-677 should document the off-label discussion, obtain informed consent specifically noting investigational status, and use licensed compounding pharmacies operating under 503A or 503B regulations.

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "We recommend against the use of growth hormone secretagogues in patients with known active malignancy and caution their use pending longer-term safety data in otherwise healthy adults." [12]. This guideline reflects expert consensus that does not yet cover perimenopausal women as a specific population, and the HealthRX team awaits forthcoming Endocrine Society updates that may address this gap.